<SEC-DOCUMENT>0001140361-24-028366.txt : 20240531
<SEC-HEADER>0001140361-24-028366.hdr.sgml : 20240531
<ACCEPTANCE-DATETIME>20240531162144
ACCESSION NUMBER:		0001140361-24-028366
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240531
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240531
DATE AS OF CHANGE:		20240531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		241010061

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20030354_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:imcr="http://immunocore.com./20240531" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_b653cef67ce246d08ded67467cfc0a13" contextRef="c20240531to20240531" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_3582702c2d9847f696b7a4ae7759fc53" contextRef="c20240531to20240531">0001671927</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_27af4dfdc73c4472ba932e4eb1a078a1" contextRef="c20240531to20240531">00-0000000</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="imcr-20240531.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240531to20240531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-31</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">
<div>&#160;
        </div>
<hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_52b9b4432e104f14aa411d20e59ccbb6" contextRef="c20240531to20240531">8-K</ix:nonNumeric></div>

      <div>
        <div style="text-align: center;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_b1e46d926151477ba6fd448e72a273f3" contextRef="c20240531to20240531" format="ixt:date-monthname-day-year-en">May 31, 2024</ix:nonNumeric></div>

      <div>
        <div style="text-align: center;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

        <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_ca06363dae04456a9a816e791ee75674" contextRef="c20240531to20240531">Immunocore Holdings plc</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its Charter)</div>

      <div>
        <div style="text-align: center;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_66e8368da80245c886147fbf65e0f515" contextRef="c20240531to20240531" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric><br/>
                </span></div>
            </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_307a77d5ae774f569c82a6208d0e6f07" contextRef="c20240531to20240531">001-39992</ix:nonNumeric></span></div>
            </td>

    <td style="width: 33.34%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;"><span style="-sec-ix-hidden:Fact_27af4dfdc73c4472ba932e4eb1a078a1">Not Applicable</span><br/>
                </span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Commission File Number)</div>
            </td>

    <td style="width: 33.34%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_cf99ea2e2bd2404dabf329da97d1c1be" contextRef="c20240531to20240531">92 Park Drive</ix:nonNumeric>,
                <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_bdcdaf9f15484def887b5731cb757269" contextRef="c20240531to20240531">Milton Park</ix:nonNumeric></div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine3" id="Fact_af2d7528376c4f80a2f7398f5206fc9b" contextRef="c20240531to20240531">Abingdon</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_9bf9a101a67f495e81ded8407f96cc31" contextRef="c20240531to20240531">Oxfordshire</ix:nonNumeric> </div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_b1ba7a26c10a463b86a906f3333b49da" contextRef="c20240531to20240531" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; text-align: center; font-weight: bold;"><br/>
              <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_f06e0be94aeb44ddbaa1469c1f531c11" contextRef="c20240531to20240531">OX14 4RY</ix:nonNumeric></td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Address of principal executive offices)</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">+<ix:nonNumeric name="dei:CityAreaCode" id="Fact_923dcef74c1d46979714bf1ce6a42254" contextRef="c20240531to20240531">44</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_59a58f3e437a4b898e62be7ee4ba40b4" contextRef="c20240531to20240531">1235 438600</ix:nonNumeric></div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former name or former address, if changed since last report)</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div>
        <div style="text-align: center;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

        <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6pt; font-size: 10pt; font-family: 'Times New Roman';"><br/>
            </td>

    <td style="width: 21pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_4ed640e0acff4bf489b333a71723f6d7" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -21pt; margin-left: 27pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6pt; font-size: 10pt; font-family: 'Times New Roman';"><br/>
            </td>

    <td style="width: 21pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_cb99035734f84811aeb4954f274a3f5f" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -21pt; margin-left: 27pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6pt; font-size: 10pt; font-family: 'Times New Roman';"><br/>
            </td>

    <td style="width: 21pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_e026b1ad1f9c462d83a74f700df377e3" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -21pt; margin-left: 27pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6pt; font-size: 10pt; font-family: 'Times New Roman';"><br/>
            </td>

    <td style="width: 21pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_35841a4f04b34f118d17b365b695515e" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 37.9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 0.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 15.72%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Symbol(s)</div>
            </td>

    <td style="width: 0.92%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 44%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 37.9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman'; text-align: center; font-weight: bold;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_bba311dfde52415c96a59a9abb89431e" contextRef="c20240531to20240531">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 0.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 15.72%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman'; text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_b08a45573b414c65954610db6a65404b" contextRef="c20240531to20240531">IMCR</ix:nonNumeric><br/>
            </td>

    <td style="width: 0.92%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 44%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman'; text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_939045d191f5431aa446d03569fa9e81" contextRef="c20240531to20240531" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 37.9%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; text-align: center; font-weight: bold;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ordinary share, nominal value &#163;0.002 per share*</div>
            </td>

    <td style="width: 0.54%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 15.72%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">*</div>
            </td>

    <td style="width: 0.92%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 44%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">The Nasdaq Stock Market LLC</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">* <span style="font-style: italic;">Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.</span></div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (<span style="color: rgb(0, 0, 0);">&#167;</span>230.405






        of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (<span style="color: rgb(0, 0, 0);">&#167;</span>240.12b-2 of this chapter).</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_76d30e36ec5e44fc9c13494b69194cde" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">
<div>&#160;
        </div>
<hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 7.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Regulation FD Disclosure.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On May 31, 2024, Immunocore Holdings plc (the &#8220;Company&#8221;) issued a press release announcing updated data from the Company&#8217;s Phase 1
        clinical trial of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients. As disclosed in the press release, the Company is presenting such data at the 2024 American Society of
        Oncology (ASCO) Annual Meeting on May 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">As discussed in the press release, the Company will host a conference call and live audio webcast today, May 31, 2024 at 7:15 p.m., Eastern Time, to discuss the Phase 1
          PRAME expansion data and the Company&#8217;s Phase 3 registrational trial in cutaneous melanoma. The live audio webcast may be accessed through the &#8220;Events &amp; Presentations&#8221; page in the &#8220;Investors&#8221; section of the Company&#8217;s website at
          www.immunocore.com/investors.</div>

      </div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and
        shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of
        the Company&#8217;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by
        specific reference in such filing.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="color: rgb(0, 0, 0); font-weight: bold;"> Financial Statements and Exhibits</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);"><a href="ef20030354_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Press Release dated May 31, 2024.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">104</div>
            </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
        hereunto duly authorized.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="vertical-align: top;" colspan="3">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">IMMUNOCORE HOLDINGS PLC</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: middle; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 40%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" rowspan="1">&#160;&#160;&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left;">Dated: May 31, 2024</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left;">By:</div>
            </td>

    <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left;">/s/ Bahija Jallal, Ph.D.</div>
            </td>

    <td style="width: 7%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left;">Name:</div>
            </td>

    <td style="width: 42%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left;">Bahija Jallal, Ph.D.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left;">Title:</div>
            </td>

    <td style="width: 42%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
      </div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
      </div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20030354_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div style="text-align: right;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div><br>
      <img src="image00026.jpg">
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024</div>
      <div>&#160;</div>
      <div style="text-align: center; margin-left: 3.3pt; font-style: italic;">Monotherapy brenetafusp (IMC-F106C) in late-line cutaneous melanoma demonstrated promising disease control (partial response and stable disease), progression free survival
        (PFS), and ctDNA molecular response</div>
      <div>&#160;</div>
      <div style="text-align: center; margin-left: 3.3pt; font-style: italic;">Clinical activity was enriched in PRAME positive patients with 58% disease control rate and 4.2 months median PFS</div>
      <div>&#160;</div>
      <div style="text-align: center; margin-left: 3.3pt; font-style: italic;">Peripheral blood T cell fitness was associated with increased brenetafusp clinical activity and was higher in earlier lines of therapy</div>
      <div>&#160;</div>
      <div style="text-align: center; margin-left: 3.3pt; font-style: italic;">Brenetafusp is well tolerated as monotherapy and in combination with anti-PD1</div>
      <div>&#160;</div>
      <div style="text-align: center; margin-left: 3.3pt; font-style: italic;">Currently screening patients in a Phase 3 clinical trial (PRISM-MEL-301) of brenetafusp with nivolumab in first-line advanced cutaneous melanoma</div>
      <div>&#160;</div>
      <div style="text-align: center; margin-left: 3.3pt; font-style: italic;">Company to host a live webcast and conference call today at 7:15 PM ET / 6:15 PM CT</div>
      <div>&#160;</div>
      <div style="text-align: justify;">(OXFORDSHIRE, England &amp; CONSHOHOCKEN, PA &amp; ROCKVILLE, MD, US, 31 May 2024) <u>Immunocore Holdings plc (Nasdaq: IMCR) (&#8220;Immunocore&#8221; or the &#8220;Company&#8221;)</u>, a commercial-stage biotechnology company pioneering
        and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today released Phase 1 data with the first off-the-shelf ImmTAC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> targeting PRAME, brenetafusp (IMC-F106C), in patients with late-line, post-checkpoint cutaneous melanoma. Brenetafusp was shown to be well tolerated, in monotherapy and in combination with
        anti-PD1, and demonstrated durable clinical benefit.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">&#8220;Brenetafusp continues to demonstrate promising monotherapy clinical activity in late-line cutaneous melanoma patients who were previously treated with checkpoint therapies,&#8221; said <font style="font-weight: bold;">Dr.</font>&#160;<font style="font-weight: bold;">Omid Hamid, Chief, Translational Research and Immunotherapy, Co-Director, Melanoma Therapeutics at Cedars-Sinai Cancer at the Angeles Clinic and Research Institute</font>. &#8220;The disease control and PFS benefit for these
        brenetafusp-treated melanoma patients compares favorably to data with other immunotherapies.&#8221;</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 1 of 9<br>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00026.jpg"></div>
        </div>
      </div>
      <div style="text-align: justify;">&#8220;The best measure of brenetafusp monotherapy activity is disease control, which is observed in 56% of checkpoint pre-treated melanoma patients,&#8221; said <font style="font-weight: bold;">David Berman, Head of Research
          and Development</font>. &#8220;We expect brenetafusp PFS to be even higher in first-line based on our analysis of blood T cell fitness. These data points, in conjunction with the significant molecular response and the expected additive benefit of
        combining with an active anti-PD1, provide confidence for PFS as an endpoint in our ongoing Phase 3 first-line trial.&#8221;</div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;"><u>Phase 1 data in post-checkpoint cutaneous melanoma</u></div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">As of 18 March 2024, 47 patients have received brenetafusp (IMC-F106C) monotherapy at clinically active target dose levels.&#160; All monotherapy treated patients had received prior immune checkpoint inhibitors (100%
        anti-PD1, 81% anti-CTLA4). PRAME expression was high amongst evaluable patients (median H score of 215). Only 11% of patients had PRAME negative tumors, as measured by immunohistochemistry.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Brenetafusp was well-tolerated, with treatment-related adverse events (TRAEs) that were manageable and consistent with the mechanism of action. The most frequent TRAE reported was Grade 1 or 2 cytokine release
        syndrome (CRS) and rash; these events occurred predominantly following the initial three doses. There were no Grade 3 or higher CRS TRAEs.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Of the 47 monotherapy patients, 36 had a RECIST evaluable tumor assessment. The disease control rate (DCR), consisting of partial response (PR) and stable disease (SD), was 56% including 4 PR (ORR 11%) and 16 SD
        (44%). Durable tumor reduction, confirmed by at least one subsequent scan, was observed in 28% of patients and is an attribute of the ImmTAC platform<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>. Clinical
        benefit was enriched in the 31 evaluable PRAME positive patients. The DCR in this group was 58% and included all 10 patients (32%) with confirmed tumor reduction.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Both median progression free survival (mPFS) and 6-month overall survival (OS) rates were greater in PRAME positive than in PRAME negative monotherapy patients: 4.2 vs 2.1 months and 95% vs 40%, respectively.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">42% of ctDNA-evaluable, PRAME positive monotherapy patients had a molecular response (10/24) and there was a trend for longer PFS and OS in molecular responders. No ctDNA-evaluable PRAME negative patients had ctDNA
        reduction.</div>
      <div>
        <div>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9cb28666b844c6b9d8ec2e2f11d9d39">

              <tr>
                <td style="width: 14.2pt; vertical-align: top; text-align: right;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">1.</div>
                </td>
                <td style="width: auto; vertical-align: top;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ikeguchi, Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in mUM, ASCO 2024,
                    Abstract #9529 &#8211; to be presented on 1 June, 2024: Poster Bd #313</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 2 of 9<br>
                </td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00026.jpg"></div>
        </div>
      </div>
      <div style="text-align: justify;">In addition to the monotherapy patients treated with brenetafusp, there were 9 cutaneous melanoma patients who received brenetafusp in combination with an anti-PD1 (pembrolizumab), all of whom had received prior
        checkpoint inhibitors (100% prior anti-PD1, 89% prior CTLA4). Overall, patients were more heavily pre-treated in the combination cohort compared to monotherapy (median prior lines: 4 vs 2; PD-1 refractory: 67% vs 30%). Brenetafusp in combination
        with pembrolizumab was well tolerated, with TRAEs that were manageable and consistent with the mechanism of action of both agents. There was one dose-limiting toxicity (transaminitis) reported in one patient with prior history of checkpoint
        inhibitor induced autoimmune hepatitis.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Of the 7 patients evaluable for efficacy in combination, 4 achieved disease control including 1 ongoing PR (confirmed after the data cut off for the presentation), and 3 of the 4 ctDNA evaluable patients having
        molecular response.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In 41 gene-expression evaluable monotherapy patients, a gene signature was identified from baseline peripheral blood that was a measure of systemic T cell fitness. Patients with gene signature expression levels
        greater than or equal to the median had higher clinical benefit including a median PFS of 6 months and DCR of 69%, compared to those with less than the median gene expression levels (2 months and 42%, respectively). Patients with only 1-2 prior
        lines of therapy had higher T cell fitness gene signature, on average, than those with 3 or more prior lines of therapy.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The advanced cutaneous melanoma data from the ongoing Phase 1/2 trial of brenetafusp will be presented today at 2:45 PM CT / 3:45 PM ET, in the Melanoma/Skin Cancers oral abstract session at the 2024 American Society
        of Oncology (ASCO) Annual Meeting. The presentation will be accessible in the &#8216;Events &amp; Presentations&#8217; section of the Investor Relations section of the Company&#8217;s website.</div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;"><u>PRISM-MEL-301 &#8211; First PRAME Phase 3 clinical trial with brenetafusp in first-line advanced cutaneous melanoma</u></div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">The Company is enrolling patients in a registrational Phase 3 clinical trial with brenetafusp in first-line advanced cutaneous melanoma (CM) with a primary endpoint of progression-free survival (PFS) (NCT06112314).
        The trial will randomize HLA-A*02:01-positive, first-line advanced CM patients to brenetafusp + nivolumab versus a control arm of either nivolumab or nivolumab + relatlimab, depending on the country where the patient is enrolled.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 3 of 9<br>
                </td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00026.jpg"></div>
        </div>
      </div>
      <div style="text-align: justify;">Under the terms of a clinical trial collaboration and supply agreement, Immunocore will sponsor and fund this registrational Phase 3 clinical trial, and Bristol Myers Squibb will provide nivolumab.</div>
      <div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Audio Webcast</div>
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify;">Immunocore will host a conference call today, May 31, 2024 at 7:15 PM ET / 6:15 PM CT, to discuss the Phase 1 PRAME expansion data and Phase 3 registrational trial in cutaneous melanoma. The call will also be
          available via webcast by visiting the Events &amp; Presentations section on Immunocore&#8217;s website. A replay of this webcast will be available for 30 days.</div>
        <div><br>
        </div>
        <div style="text-align: justify;">Conference Call Details:</div>
        <div style="text-align: justify;">U.S. (toll-free): 877-405-1239</div>
        <div style="text-align: justify;">International (toll): +1 201-389-0851</div>
        <br>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
        <div style="text-align: justify;"> <br>
        </div>
        <div style="text-align: justify; font-weight: bold;">About ImmTAC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> molecules for cancer</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">Immunocore&#8217;s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the
        immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector
        function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, including
        immune &#8220;cold&#8221; low mutation rate tumors.</div>
      <div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">About PRISM-MEL-301 &#8211; Phase 3 trial with brenetafusp (IMC-F106C; PRAME-A02) in 1L advanced cutaneous melanoma</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">The Phase 3 registrational trial will randomize patients with previously untreated, HLA-A*02:01-positive, advanced melanoma to brenetafusp + nivolumab versus nivolumab or nivolumab + relatlimab, depending on the
        country where the patient is enrolled. The study will initially randomize to three arms: two brenetafusp dose regimens (40 mcg and 160 mcg) and control arm and will discontinue one of the brenetafusp dose regimens after an initial review of the
        first 60 patients randomized to the two experimental arms (90 patients randomized total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review (BICR), with secondary endpoints of overall
        survival (OS) and overall response rate (ORR).</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 4 of 9<br>
                  </td>
                </tr>

            </table>
          </div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          <div style="width: 100%;" class="BRPFPageHeader">
            <div><img src="image00026.jpg"></div>
          </div>
        </div>
        <div style="text-align: justify; font-weight: bold;">About the IMC-F106C-101 Phase 1/2 trial</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumor cancers including non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), endometrial, ovarian,
        cutaneous melanoma, and breast cancers. The Phase 1 dose escalation trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C
        (brenetafusp), a bispecific protein built on Immunocore&#8217;s ImmTAC technology, and the Company&#8217;s first molecule to target the PRAME antigen. The Company has initiated patient enrollment into four expansion arms in cutaneous melanoma, ovarian, NSCLC,
        and endometrial carcinomas. The IMC-F106C-101 trial is adaptive and includes the option for Phase 2 expansion, allowing for approximately 100 patients treated per tumor type in the Phase 1 and 2 expansion arms. Ph1 monotherapy continues in
        additional solid tumors as well as multiple combinations with standards-of-care, including checkpoint inhibitors, chemotherapy, targeted therapies, and tebentafusp.</div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">About Cutaneous Melanoma</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer-related mortality. The majority of patients with CM are
        diagnosed before metastasis and survival remains poor for the large proportion of patients with metastatic disease. Despite recent progress in advanced melanoma therapy, there is still an unmet need for new therapies that improve first-line
        response rates and duration of response as well as for patients who are refractory to first-line treatments.</div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">About KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and
        melanoma. This is the first molecule developed using Immunocore&#8217;s ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult
        patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 5 of 9<br>
                </td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00026.jpg"></div>
        </div>
      </div>
      <div>
        <div style="text-align: justify; font-weight: bold;">IMPORTANT SAFETY INFORMATION</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and
          then as clinically indicated.</font> Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8%
        being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of
        KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.</div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">Skin Reactions</div>
        <div><br>
        </div>
      </div>
      <div style="text-align: justify;">Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or
        systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.</div>
      <div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Elevated Liver Enzymes</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during
        treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.</div>
      <div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Embryo-Fetal Toxicity</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last
        dose.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The most common adverse reactions (&#8805;30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and
        vomiting. The most common (&#8805;50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 6 of 9<br>
                </td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00026.jpg"></div>
        </div>
      </div>
      <div style="text-align: justify;">For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).</div>
      <div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">About Immunocore</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; Immune mobilizing monoclonal TCRs Against X disease &#8211; designed to
        treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including nine
        active clinical and pre-clinical programs&#8203; in oncology, infectious diseases, and autoimmune diseases. The Company&#8217;s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with
        unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 7 of 9<br>
                </td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00026.jpg"></div>
        </div>
      </div>
      <div>
        <div style="text-align: justify; font-weight: bold;">Forward Looking Statements</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221;
        &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical
        facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the expected clinical benefits of ImmTAC molecules, including KIMMTRAK, brenetafusp, and the Immunocore&#8217;s
        other product candidates, including tumor reduction, disease control rate of partial responses and stable diseases, ctDNA molecular response, progression free survival and extended overall survival benefit, alone and in combination with other
        therapies; the expected efficacy and tolerability of Immunocore&#8217;s products and product candidates, including brenetafusp; expectations regarding receipt of regulatory approvals and completion of related procedures; the value proposition of
        Immunocore&#8217;s products and product candidates, including KIMMTRAK and brenetafusp; future development plans of Immunocore&#8217;s products and product candidates, including KIMMTRAK and brenetafusp; and expectations regarding the design, progress, timing,
        enrollment, randomization, scope, expansion, funding and results of Immunocore&#8217;s existing and planned clinical trials, including the Phase 3 PRISM-MEL301 trial with brenetafusp plus nivolumab versus standard nivolumab in 1L advanced cutaneous
        melanoma and the IMC-F106C-101 Phase 1/2 dose escalation trial with brenetafusp in patients with multiple solid tumor cancers including non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), endometrial, ovarian, cutaneous melanoma, and
        breast cancers, and those of the Immunocore&#8217;s collaboration partners or the combined clinical trials with Immunocore&#8217;s collaboration partners; statements regarding the benefits of the Company&#8217;s collaboration with Bristol-Meyers Squibb; and the
        timing and sufficiency of clinical trial outcomes to support potential approval of any of the Immunocore&#8217;s product candidates or those of, or combined with, its collaboration partners. Any forward-looking statements are based on management&#8217;s
        current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking
        statements, many of which are beyond the Company&#8217;s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company&#8217;s business, financial position, strategy and anticipated
        milestones, including Immunocore&#8217;s ability to conduct ongoing and planned clinical trials; Immunocore&#8217;s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products,
        including as a result of health epidemics or pandemics, war in Ukraine, the conflict between Hamas and Israel, the broader risk of a regional conflict in the Middle East, or global geopolitical tension; Immunocore&#8217;s ability to obtain and maintain
        regulatory approval of its product candidates, including KIMMTRAK; Immunocore&#8217;s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved
        products; Immunocore&#8217;s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to
        patient enrollment delays or otherwise; Immunocore&#8217;s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market
        opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval;
        Immunocore&#8217;s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including inflation, interest rates and unfavorable general market conditions, and the
        impacts thereon of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tension; Immunocore&#8217;s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or
        its collaborators are developing; and the success of Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements, including the risk that Immunocore may not realize the anticipated benefits of its collaboration with
        Bristol Myers Squibb. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the Securities and Exchange Commission, including Immunocore&#8217;s most recent Annual Report
        on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 28, 2024, as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s subsequent filings with
        the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 8 of 9<br>
                </td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div><img src="image00026.jpg"></div>
        </div>
      </div>
      <div>
        <div style="text-align: justify; font-weight: bold;">Contact Information</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify; font-weight: bold;">Immunocore</div>
      <div>&#160;</div>
      <div style="text-align: justify;">S&#233;bastien Desprez, Head of Communications</div>
      <div style="text-align: justify;">T:&#160;+44 (0) 7458030732</div>
      <div style="text-align: justify;">E: <u>sebastien.desprez@immunocore.com</u></div>
      <div style="text-align: justify;">Follow on Twitter: @Immunocore</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">Investor Relations</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Clayton Robertson, Head of Investor Relations</div>
      <div style="text-align: justify;">T: +1 (215) 384-4781</div>
      <div style="text-align: justify;">E: <u>ir@immunocore.com</u></div>
      <div style="text-align: justify;"><u> <br>
        </u></div>
      <u> <br>
      </u>
      <div style="text-align: justify;">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;"><img src="image00027.jpg"></td>
                <td style="width: 33.33%;"><img src="image00028.jpg"></td>
                <td style="width: 33.33%; text-align: right; vertical-align: bottom; font-size: 8pt;">Page 9 of 9<br>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>imcr-20240531.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<xs:schema targetNamespace="http://immunocore.com./20240531" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:imcr="http://immunocore.com./20240531" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20240531_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20240531_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://immunocore.com./role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>imcr-20240531_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>imcr-20240531_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://immunocore.com./role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="imcr-20240531.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://immunocore.com./role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00026.jpg
<TEXT>
begin 644 image00026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  8 .<# 2(  A$! Q$!_\0
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M'WB/8-N['?&,UE2;5*\)<NK_ "1I-+VGOJ^AN0?!;0H95D76/$A*]FU#(_\
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;N_P__P! CQ+_ ."__P"RHHHK?ZA1,OK50__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00027.jpg
<TEXT>
begin 644 image00027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  W 'P# 2(  A$! Q$!_\0
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MP;$9&N#?3F\9A(9MJ_ZP,6W;<8[D8Z4[4Q>^6-/\66-P)FG=(8DD,:N6SO\
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M#&_F0IG:0NW:(N!]WOUQ[5V49)4%A@XY%<HGC O+!#_9L@FNEC>V4S+B0.6
MR?X>$)[U6TGQ;,(&%W;/*\<K&X8.H\E#*40#^\>/;C\JF49RW*4HK8[:BN/'
MC1C&9?[,E\KRC.&\T<QAMK'&.HZX[UUT;AXU<=& (J)1<=RU)/89=6\-W;O!
M<QI+"XPR.,@BJ=GHNG6;1-:V<,;1%BA5>06ZGZG HHI7861+:Z996C(UM;1Q
MF-#&A4?=7.<#VS4UK:P6D(AMHDCC!+!5&!DG)HHHNQV*R:/IZ1M&EI"$:(PL
MNW@H23M^F2?SHFTFSDCE4PJ#*JH[#@E5^Z,^@HHHNQ607^CV&H/$]]:0SM&,
M*77) ]/I2S:183(RRVL3*SF1@5ZL1@G\CBBBB["R(9] TN<R&:Q@8R$%B5ZD
M# /Y<4[^PM+^UI<_88!/'MVN%P1M&!^0XHHHYGW"R)IM+LIA()+>-O,D$K9'
M5QT;Z\5&NC6"0M'':Q(I*MP.ZC"GZCM111=A9&/I?@ZRM9+AKL1W0E18]IB5
M0 K%@>.K9)YK47P_I*&W*V%N/(.Z/Y/NG.?Y\_6BBFYR?42BD2_V18>7L^R1
9;/+,6-O\).2/IFKRJ%4*HP , 445-RC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00028.jpg
<TEXT>
begin 644 image00028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  V )H# 2(  A$! Q$!_\0
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MIK7B2&">2>":7[#M,JK;<W <M@+QV!3./>NRUS4UTG3VNFB>;YUC5$(!9F8
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C6/\ NA0!^5(EO#&JJD2*JG*@*  ?:BB@"6BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139964821983808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunocore Holdings plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">92 Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Abingdon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Oxfordshire<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 438600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMCR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "U@K]8>2?[N:4$   1$@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*6887/B-A"&_XK&G>FT,TFP!2&0 V8(R=TQ=TEHH+UK._T@;($UL257$@'^
M?5<&;.[.K)EI/@3+EEX_6JUV5^ZME7XU,>>6;-)$FKX76YO=-AHFC'G*S)7*
MN(0G"Z539J&IEPV3:<ZB?%":-*COMQLI$](;]/)[$SWHJ95-A.033<PJ39G>
MWO%$K?M>X!UNO(AE;-V-QJ"7L26?<OM[-M'0:A0JD4BY-$))HOFB[PV#VSO:
M=@/R'G\(OC9'U\1-9:[4JVN,H[[G.R*>\- Z"08_;WS$D\0I <>_>U&O>*<;
M>'Q]4'^?3QXF,V>&CU3R140V[GL=CT1\P5:)?5'KCWP_H6NG%ZK$Y/_)>M>W
MU?)(N#)6I?O!0) *N?MEF[TAC@9T_!,#Z'X S;EW+\HI[YEE@YY6:Z)=;U!S
M%_E4\]$ )Z1;E:G5\%3 .#NX5^$*C&P)DQ%YD%;8+1G+W6J#U7H-"R]Q71OA
M7O!N)TA/"#ZR+6D&%X3ZM/7MZ :@%7RTX*.Y7/.$W$B]<4W^'LZ-U;""_U0!
M[11:U0K.K6]-QD+>]\!O#==OW!O\_%/0]M\A?,V"KXFIE_:;;3->!8</[UQ^
M0B!:!40+51D"0913O$_8LHH"'[]@B>$(QW7!<7V>,29<"^7\*2+@E95VP94.
M7E3G1NV"K(WJ[3W[O4@X>5JE<ZZKF' -WP\NF]UNER(\-P7/S3D\+WPIG&.#
MR9Y86FDG7&><IBNI0J4Y^:B22,BE(5D2(H2=@K!S#N$(EE.S!&)"Q#?D$]]6
M,>)*/ABN?1-TZ0V"U2VPNN=@C27,.5,Z#U(79&K!RXC29*16P O8*JJT)B[^
MU4<( [\,J?XYC#.V(>,(["<6(LQ!$=>KD?3]2W_WAQ$>!?W@',)A%$%$-!>'
M"_(9^I%G66FZ&LDN)1.F7\F]ABR+09:1/T #-PXY6ZM*2%SR4206EL&!8HAE
M\ _P\(TCQII76Q(7'<YA&T??Y]YO"<O,$."A_7O"D6O!1IFI=75RQ^6>-U :
M0.DG-+K&9<((\#C_ ]YN_U:2X4H?[C"@,D\$9R6* FBBC(7P]Y?(3L:4&L7G
MKT&+M%[^Q/#*M!'@\3Y?OB&4WZ=I<($6EDV#,CD$>$S_K$*PRB16$LNG-2(!
M;5Z35K/3QJ-:F1H"/'S/A(7TKA8DH+_,?R53'JXTV*N2#%>"@DI#S);DGF?*
M" OG%3*-&;C$!>$LC.$\DM>2X"QR29P18%<(Z;H9U^V"2 7%.ICHC24K3ERY
MV7SG7_D^)1G4LWDGK#HN<PW%$\-,,Y?UR72;SE5261WC N/'T0M&4N84BB>
M@[G)PR:,F5SRDR5-C=#3<'H__ UC.CH\G)5"'F YE\Y*'T#!QK!WTHS)2L>H
M$:RKE&F9.B@>Y;^ K2R7C@5*N'V!8"J1<*%:I#)74#RX3U4B0I&[]"/44UJP
M:H?Z?X<)6B8'BH?TB>:7(9B'RY#OSEAPS('=\[Q85,>;&KU:LC)+4#RF_T V
M-F8%9+6 N.Q)P,;1 =]]+'EDSI\-2?@"A/RK&YBXWGU_V#6LRO(S_UQ9J]+\
M,N8,V%P'>+Y0RAX:[C-"\15H\!]02P,$%     @ M8*_6)^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ M8*_6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "U@K]81TOHN.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "U@K]8F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +6"OUAY
M)_NYI00  !$2   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "U@K]8GZ ;\+$"  #B#   #0
M    @ 'I#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +6"OUB7BKL<P
M !,"   +              "  <4/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M +6"OU@<.&7J/P$  #P"   /              "  :X0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "U@K]8)!Z;HJT   #X 0  &@
M@ $:$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "U
M@K]899!YDAD!  #/ P  $P              @ '_$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  !)%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20030354_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immunocore.com./role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20030354_8k.htm">ef20030354_8k.htm</File>
    <File>imcr-20240531.xsd</File>
    <File>imcr-20240531_lab.xml</File>
    <File>imcr-20240531_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20030354_8k.htm": {
   "nsprefix": "imcr",
   "nsuri": "http://immunocore.com./20240531",
   "dts": {
    "inline": {
     "local": [
      "ef20030354_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "imcr-20240531.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imcr-20240531_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imcr-20240531_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://immunocore.com./role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240531to20240531",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030354_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240531to20240531",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030354_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001140361-24-028366-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-028366-xbrl.zip
M4$L#!!0    ( +6"OU@LN\I&3Q4  &V1   1    968R,# S,#,U-%\X:RYH
M=&WM7>EWVSB2_YZ_ JM^VW%F=/"F*#N>Y\AVMZ;CX]GNU[W[91Y(@!(Z%,DF
MJ=C:OWZKP$/49<NV?"2QWTQ')$"B4*CZU8&#>_^Z&0?D*T]2$84?WZMMY3WA
MH1<Q$0X_OC^X[ \&[_^U_VYOE$$UJ!JFO1LW"<3'QBC+XEZG<WU]W<8[[2@9
M=C1%T3LB3#,:>KQ1U ]$^.66ZECLTK2J?K-4_UJ7M57'<3JRM*J:BE45X;5J
MY\^3SY?>B(]I:Y$>;)[-'JQ38W7RPK*J2"-#4^W;.IO7*!](DZRJ[-/4E17A
M)E36].JM-^M>J"+WH(?\ST\7GV?5L]7U9U4[64+#U(^2,<U@'+$UI:5H+56K
MO:25<F_N17#='D9?;WV/:K:4;DM7R_=,TM:0TGBYDT7!7$<97V!SV2(4S%7T
MHDF8)=/5E8O"^0<F20)BNNZ)HG2>F"QI9=.8IZN9"<4=+,9GM):BU_N<)6LE
MP.E :5DQI,)+5Y,DB^;H286WNBH4S%?,XF1-32B9J\IOO-'JJE@RST'NKV$>
M]^>E=>S-FA?C\22,O"CA;2\:M[&BH9@5J]:K+>)'8_\=(7LC3AG^@)^9R *^
MO]?)_\WO_5>K13X+CX<I9R2+>N13$E&6"#;DLH+\.XR\R9B'&?$23C.H.$D!
MKVI5R?G%F2\"3C2CK;?5MJEIQNSQ?A1/$S$<902(,TF+8#?J3[=:!35CGE&"
M?6KQOR?BZ\=&/PHS:+AU!:+2(%Y^];&1\9NL(_O8 ;#LY'U\M^=&;$K2;!KP
MCPT?ZK9\.A;!M$?>7XDQ3\DIOR87T9B&[W>)+$_%__$>494XVR7XSA8-Q##L
MD8#[<,>+@BCID9\4^;=+7.I]&2:@'JQ5%OGR;Q=8O<?$5R+8Q\;AY?FQ0.W^
M53#&PT9)$!-I'% @)HQ"#D_LB9L>$LZ3_*>L+7]"A5/@=R(\$M(Q/LI%[P &
M@.$@' =TV) M'5,O^X]KF3K(D&5[7#,LIG099Y9MP+7O*535"Z[=9!<H@5XI
M05DTDZ4<@#XV +1ZOKCA#/@6@(78E__L=>9(6D_A40B"->T#B0D-!B'C-[_Q
M:8U2W>QJMJ)Y&G.ZANU;CN7:U*#<MDW']\P-*-V'85 M6W4T^YY47=&; ; W
M$[[P)-9"19<G->HTF_H&\YEGZYYAV)I+'5WC!G=5JMA=JFY$72L7%66)NL[\
M""?<YPB9/-W?0PO;2Z7MA%<3:7%[HP1;02QHE>]OWZ2L410C<GYLI&(<!QQ4
M0+Z^_DYYF4:31%Y)#Z)7D"][O)+\HAZ7#"NO1,$UGA!)(U]ITOJ#W^8'9_'A
M_?+6_-MCX$[$RBOP&Y+L$ !F'XEJ*288A?*Y65E%)EM3M2PIK\M&.G-\*)E6
M<:E3T\<.*#, "B 2_MA+8QK.X4H=-^X FL8^V>O@"Q;?FB/>*"E?[$8)M%W
M \FO6FZ49=$8FHIO2!H%@A$W !2JRK,H[A%CL7#$$6TE@3<S&"NPZA88F\-
ML D93W;)F"9#$;80$GN$3K*HNI7DK<A[",2R0U77\M]E[U:]N6@]&;H[2I/@
M_S[<R<XYW#8J_E\7/7:C@ '+?S\=7!T=DLNK@ZNCRQG?7Y:HRZ/^[Q>#J\'1
M)3DX/21'?_9_/3C]Y8CTSTY.!I>7@[/39Z946T?I'P>7OPY.?[DZ.VV2PW:_
M#0;;-)SUU-U?)Z2YW/_Y)]52=BM'H6B@IA.E(&MU.;[%')=%J]@UKU\;2_4S
MCTEWW9@<GUV<D+56KO30<C^I,FJFYCJN88 A4Q7#5PU*#55EFL)-Q_-<U]K
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MDLF/5)%W\E:R>&L+ +I%KC_:B9)8AX%Q!.%H0OZ":#1E(H^8P:L2=5S\\"3
M\IJXT8_&8Y'BJ@J"V$!R<'A<OV_1U]?4]<'%)3D:QT$T!3&8G^4BIU%[$QXL
M:4SQXQW<1<6\*Z/_YBU^H]ZBX6Q9P+<;*=[A!1PPEO T+?[Y#%9)K<?7ON-P
MJG'-96#>#49=7]<<1AV;J9[J\@W< 4<CYS3Y0@X3\75I(KRY;*+N2ZY6SW@Q
MCU'?\573Z!J,^]VN[9JVKGJN;=J:Y6Q [HD(,E!Z)'E-(NM;'%.]QB3J:\PV
MM:YN6Y[A=Q6J^;;N='U34RS?<]P-F'3@@B:S*%P:S@V'KP\_SY*KZ#JLT>6X
MOD-51:66[1N.R;LJXZQK*+;O6)ZG;[)ZX.P&X@N6CD2R)&GD6QN](@2;R^>Z
MU*::Y:D*-2S=[5K4@2'3X<\U0"D?$'X541>2@)'7[Z' I4F_R=$=;Q)V/<8Y
MT+;GR)>YS0U;7@G9^3J!^[>^,LVT<MQ7\6\C63B/THP&_ROBA8#<5RRNN-PQ
M*'<-@S&74M6 F$WU8;0]=2.5^5,UB''Q/\M@M\V 8*V-?$5!VT[!;/3\XP1\
M?Q'3@/ ;[DTR,%UP&UQ"GC[*'WYE(O_:1@ DG*"(/X>__:00_\^U>HVF[R#A
M=$&3'4UG'O=MPU,9:+#MV*KA^JK'+6IHFKG)1(:Q-/.V'ET^1R %YZ,H7,X
MF0XUN[[.#=VFAMMUNMS27&YS;KC44-Q-*%$UW22&WK56K>)[UJ4@ZR.^V932
MSS]U-=7>30'' QXC3T@HF=+$!$ PP:B%4!@R(&<FFM_7K/1B#NF5#-(QN"L0
MD.>S7(GT7N"2YC@-P^.3?-4 @!T,%2<!3<NI\X<M<WB"3I#;9P[?)N"^K;GP
M/(=P7\EH[/='W/LB5[W0.$XB<# P]>A&-\3E072-LHR%*/&DV_J-^") W!$I
M@%#&0R:W%H"8CR=!1D,>3=)@2E*:B=2?RB>+!R(7Z*1E!A,+:G/#,O-,:#@M
MR_PH@,;AN8JO.!<C, >8]MYF.1?S5AX 3)IO3_@,/+W"A[:4PGKZ/)55,>L1
MW,LYN*FWJV(+*YW.K>#M+:'T'XG(0&TPI3T)BTQN6O-R#,XL0^$*]7P?'"VC
MZ[@01E-;M37=M]@&\UQ+L;0;18%+09\RT&J$&,<VC-V[XJJUS,O!<"7SUN#1
M8WWX_8)IT/4ZUTA<6T]X,0$U,32S@)*%57RX>&]'M4G_^()HNM*&BL^6.L^Y
M(D),WO=(*Y>].?.BV?$;4KTAU2M#JLL(O&Y0GW!X AX!N 5!/?_N.HZBF[9N
M^%VCJZJ8YW%,P]=L@^J^Z?^0,#7C&.AWSK)EC%(-VE*U&DS-K3"N0,I0VGG-
M-YQZPZDWG+H%I\X3CMX4[HZ4NV0P)DG.?'\N><05S7)5RE3?\0Q+8UUPJ0S?
M5A3FZ[;-[[GD_#O!*^!<RZNQ[D[_2C582]MQ/VR&7GG=-_QZPZ\W_-H<OP9I
M.N'):A33S:ZA4L-7#!<<+U7M,M5V=<MT+<<T57.#50]O* 8HIO.6L>-MAF)%
MW:="L<<)^?U2R?>7V5H$G2?K>,+9'$.K;7S2+!3).V#B+3FZK7;Y!US6I=OM
MVU8)+!PNH%7G!ZP L*><7%TUY7"%A]/DFPJ]46ZB'C-IK;3-56LXGYP3]YSA
M5LVVO6I^?0V=A:#,Z'T@[Q\[/W254%2@!RU/V@H!E],Q_-IYW,(&I>W<@_<O
M)B/&BPCR%E3ZM-CH)S6:EV84+,+U2,"=F=EX^K7]+X*+&R^R>@D-6I_;RPW[
M5-5<B<GUQ7PNU565^8R;FJ&:GF-1TZ$.==VN8^CJ)BMK#V1S$ <=\CA*14:3
M*;D<T82GS5Q.$A[#!2YFQXG!$.?0 6JP6HK5FB2,QG =D*\TF'""NJ3O*FU%
MT4B,AQ5AI:=>!/A]&I=G%_NU(EB8EQSDZ_*G=*EAFK;N&JKA6:9C&I:J,->B
MEFE X+/)SNF3_L7=XO%F0EZ#&)1(5$9@"_OH'=U1#).ICNJ;@#Z4&G@.GFY:
MCD\=WMU@(>E2Q(M&JEQ7? 71RBE-&?V;7&:1]X6<T.0+S\CGS_W["]"3FJ_O
MRBZ=W1_N__&$6/[B(/T\GMMC1^V10W KB+XL.GX;_+\5K%Y)=NH^"T<?NF+M
M'V1%EAU_]PCXFH'PBG6C /PDR[V,)G$G&7B:P11/'@&3$19YJVN1C63.*H P
M17JC10IKK0N+L<TM(]%>G;1_]4P=A PSIIRX4^+))8%CW!QW/>)R!_+">CV1
M$N -!R8-D6G#)+H&/GK1.,8U?#0EC/LBS,]YR5?F*"99/EQK=J:63G;F!G7U
M+ LRPMXM."S7\2CFN_ROE&K9") 'WD2,)\O@\MP\ZZNY+6T%#:L.^'H ,9@K
MGK50(Z#]4I(@UZD^1!2.U@SK'5N"RL=^D4_U\X=JKIQM,5WANL4]DQN&[SF>
MJAN.X5J.ZA@>>\K)BV],%?U;E O7_J_45+&TJ'8$>L@# #K0PS"2Z?I)RF4M
MH+)8NHN'U L)A?E1NA(UL:U@BHU+?,3!#X%D*$GX5Y%R5JD;:#D-/5SH0CVY
M9P\?PF\$,)JP-%^TR];-&>@[M)HSJ*MAFU0CN;V1V_!4TEM/ZETZC+=^4N_2
M,;XO<U+O"IX5<\&?+LZ/S^F0?THX_8);?:K9$"_@-)'NT*AZ;=XGI3:)7IU7
MG(OIC(GKVJC>'\.=EHNW6M3/D+TTN*;3=-Z1JHU"WF+.<,F]5=,OI6<YX_1]
MMP'4^WW765H_P+2[K=TU";[=S3V#C(^)W5;4]BN>7[[-"5C9JPL^G 3Y1H?C
M0W(H4B^(TDG"V]^DD_[7!/QB?[JPND:7*S0>*Q2-_;.0U$_H;)(UAQZ2';01
MN"%.4W8+UT)>J;L?P!E-)V!B*(GE+MD$;!X%.T?#$)0>-95,8B8_;0'_I<1/
MHK$T.;7WR&UVYR-\3*UX[P4"5Q$$8"31P(&A @@+>4;]21J3G<%)OW6L*E;_
M0Q/M-5!^== GKB@..?0(! U#+@WB^<7!R5%3'GJ(_>.YW8XC 081B&YEQ:<W
MO$FQA8:,>4!#8!N)09* Y6F;'(!7G0M3[E=C%^9ZW*SW"EWT6I(]G7BCO/LT
MD]7D9SJJ*.<R\@3/</=-U?NS$(=W."4[!Y?]LP_D( PGP(43SHNL_=S( 7D@
M#G&U?V=^*#!<R#(*O688'!S=C(0K,N(X;14= NDO]^6'9K+R_%G4GG++$9ZW
M)O<;E:<>P6O ^:D^B@#XGW 1OIBG_;0Z,F]GM^AG%@(U23<3J&L1!&04I1G!
M#:=AR7M0D$".4(![T>F$B8A<<]?#'8]9Q"AXK'5!0?FS>ZI)XO:XW21'%&<'
M(:(&>ILH"P5%LN5%A22Y(H'W&J/7"B*22S0TOEZ?]<HE1DBNM!G3 $O:UI:1
M_8J.C*$'+D<?ETMN92-P*(9YYJ! I2,\'CDE/],QV*+S7//R%4@%4!'T@DH^
M%P\-PJ\\S:*DJI-RK[Y%;K%+0 ]XZT!(5F,*?JQC_F-"'5&^=U$GODL-P4$3
M8?6I+1E'TC+]4#D9562^'FGJ&ZOG0 H!)HN:B$(NQU)_DH0BE7@6SJ*A=(3*
M@+$6" OC$,*Q<J3Q"TJL'&6,L2 BB@'*Y:D.5434W3!!T408I>,\AJO;QGKE
MTD VJX/DKB%V U/@_@7MY<"+TDY=$>1-R<9!00LI;$K56M6I]5 ,)BTJ-G)6
M;%DER?FNT'3]=JTB+U3OJ>S(8K#8K')48\H@*.8^.@]0448:LCH:?SF$D=]$
M-(#0-"C.TT!*AV#4$PD)M5/U""#"<%)HK+2>.<5-7.3 X_PX8\D9%\-IB9NX
M\97+O",$S>YT)A:E1U!G4_VE3V^YWJ*7I]E$+]'%>8H0IH+,EXEBR'&5V9&'
M48ZE=4,\*(!QDY5[+QC._( +0]5MSG A=9C9_MA0[SW7MLUY[(VGVN9XNLV3
M<$M'X#1J;^&@X%<S2-WO:Y0.>>HE(L:"YSI,>-50/NS@JFTKV],>G[5^#&'
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MHXEY[KN<C6>MY>K^CG:5+0[J;25.NC:=M8Z\9@%$:V^L1OG45&"2&2P1[=M
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M/OC\^(!'];>='=';VA2O=U[M;6UOO=X>/3C=XT"\*=_FR@QT$/! _ZXKD@S
MJUJ]&^,^88^85(8*_QK4*^W O]]*Z*^/Q.]>U)5+3QYM<<?@+A=X5IZ -53D
MJ(3MNMZGU[O6%DLV]_":>+&]M]/?>;TW_+I5U=DC+".TLU(Z>:65LAW;53Z@
MAV?KX,]H'>Q_9^O@=J7U;U7VW)U*_;/]Z<W+21(LZ8=Y$87PP_\#4$L#!!0
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MXHYY5$H/F>HIR"8'M* 8+F0I_G1@2;*9.$+\<+]0@3DG^ES)2.TJ!%'&4GD
MZG>:%.Q4>D*6RU665#?1N5)YHZ:>DD;CP)HQJ@MT.L<Z^F#]K&Y&<OM^>317
MBE@D5B84E I4[4KN@=E;DB914K#OI)_830--PE3!1R^HIP<)'%#5QW/A%/2J
M@Q00S[9M2#3N%T]#74A;)F4PFSI!I45I/2!Y33%?!YA-O3Q[\YM3>G5_CZF"
M2[NPGJA)Z(!J>WP79(W>=>@:.LV8;1CM&%%E1:5YOS!;5)+8YER&6Z\7D+\
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M,#,U-%]E>#DY+3$N:'1M4$L! A0#%     @ M8*_6.E/O,9' P  0@\  !$
M             ( !SSD  &EM8W(M,C R-# U,S$N>'-D4$L! A0#%     @
MM8*_6 ?PY8IZ"   ,%8  !4              ( !13T  &EM8W(M,C R-# U
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( +6"OUB/?='QWP4  /<^   5
M      "  ?)%  !I;6-R+3(P,C0P-3,Q7W!R92YX;6Q02P4&      4 !0!'
) 0  !$P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ef20030354_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imcr-20240531.xsd" xlink:type="simple"/>
    <context id="c20240531to20240531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240531to20240531"
      id="Fact_b653cef67ce246d08ded67467cfc0a13">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240531to20240531"
      id="Fact_3582702c2d9847f696b7a4ae7759fc53">0001671927</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240531to20240531"
      id="Fact_27af4dfdc73c4472ba932e4eb1a078a1">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType
      contextRef="c20240531to20240531"
      id="Fact_52b9b4432e104f14aa411d20e59ccbb6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240531to20240531"
      id="Fact_b1e46d926151477ba6fd448e72a273f3">2024-05-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240531to20240531"
      id="Fact_ca06363dae04456a9a816e791ee75674">Immunocore Holdings plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240531to20240531"
      id="Fact_66e8368da80245c886147fbf65e0f515">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240531to20240531"
      id="Fact_307a77d5ae774f569c82a6208d0e6f07">001-39992</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240531to20240531"
      id="Fact_cf99ea2e2bd2404dabf329da97d1c1be">92 Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20240531to20240531"
      id="Fact_bdcdaf9f15484def887b5731cb757269">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="c20240531to20240531"
      id="Fact_af2d7528376c4f80a2f7398f5206fc9b">Abingdon</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="c20240531to20240531"
      id="Fact_9bf9a101a67f495e81ded8407f96cc31">Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="c20240531to20240531"
      id="Fact_b1ba7a26c10a463b86a906f3333b49da">GB</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240531to20240531"
      id="Fact_f06e0be94aeb44ddbaa1469c1f531c11">OX14 4RY</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240531to20240531"
      id="Fact_923dcef74c1d46979714bf1ce6a42254">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240531to20240531"
      id="Fact_59a58f3e437a4b898e62be7ee4ba40b4">1235 438600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20240531to20240531"
      id="Fact_4ed640e0acff4bf489b333a71723f6d7">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240531to20240531"
      id="Fact_cb99035734f84811aeb4954f274a3f5f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240531to20240531"
      id="Fact_e026b1ad1f9c462d83a74f700df377e3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240531to20240531"
      id="Fact_35841a4f04b34f118d17b365b695515e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20240531to20240531"
      id="Fact_bba311dfde52415c96a59a9abb89431e">American Depositary Shares, each representing one ordinary share, nominal value &#xa3;0.002 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240531to20240531"
      id="Fact_b08a45573b414c65954610db6a65404b">IMCR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240531to20240531"
      id="Fact_939045d191f5431aa446d03569fa9e81">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240531to20240531"
      id="Fact_76d30e36ec5e44fc9c13494b69194cde">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
